- Jul 24, 2020
NCT04236011: Phase 1: BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Myeloma
NCT04236011: Phase 1: BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma This is a single arm, open-label, multi-center prospective study to determine the safety and efficacy of GC012F CAR-T cells in patients diagnosed with BCMA+ refractory/relapsed multiple myeloma (r/r MM). Sponsor Shanghai Changzheng Hospital Collaborator Gracell Biotechnology Ltd. Clini
224
- Jul 24, 2020
NCT04221178: Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
NCT04221178: Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission NCT04221178: Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission This study will test whether stopping maintenance therapy in people with multiple myeloma in MRD-negative remission has the same effect on disease control as continuing this therapy. The study will look at whether people currently on maintenance therapy can safely stop this treat
46
- Jul 24, 2020
AMaRC 19-02 - BelaCarD - Phase I/II - Study of combination belantamab maf, carfilzomib, Dex RRMM
BelaCarD Study AMaRC: (PHASE I/II) BELACARD FOR RELAPSED REFRACTORY MULTIPLE MYELOMA A phase I/II single arm study on the efficacy of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma AMaRC 19-02 - STUDY TITLE: A phase I/II single arm study of combination belantamab mafodotin, carfilzomib and dexamethasone in patients with early relapsed multiple myeloma (BelaCarD) Australasian Myeloma Research Consortium TIME FRAME
95
- Jul 23, 2020
NCT04483206: Phase 1: Personalized Autologous Transplant for Multiple Myeloma
NCT04483206: Phase 1: Personalized Autologous Transplant for Multiple Myeloma Personalized Autologous Transplant for Multiple Myeloma This phase I trial studies the best dose and side effects of mephalan in treating patients with multiple myeloma who are undergoing stem cell transplant. Chemotherapy drugs, such as mephalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading
42
- Jul 23, 2020
NCT04513639: Phase 2/3: The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study
NCT04513639: Phase 2/3: The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study Dara-Kd The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study The REMNANT study will evaluate whether treating minimal residual disease (MRD) relapse after first line treatment prolongs progression free survival and overall survival for myeloma patients versus treating relapse after first line treatment at progressive disease. To establish a homogenous gro
197
- Jul 23, 2020
NCT04483739: Phase 3: EMN 24 - Isa-KRd vs KRd New Multiple Myeloma Eligible for ASCT - IsKia TRIAL
(IsKia TRIAL) (IsKia) - (EMN24/HOVON503) NCT04483739: Phase 3: Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) (IsKia) IsKia trial (EMN24/HOVON503) Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) (IsKia) This protocol is a phase III study designed to compare the efficacy and the safety of Isa-KRd induction, transplant, Isa-KRd
255
- Jul 18, 2020
NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)
NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON) Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON) Evaluation of the effect iberdomide combined with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma. Sponsor Amsterdam UMC, location VUmc Collaborator Celgene Location Netherlands ClinicalTrials.gov Identifier: NCT04392037 Official Title: A Phase 2 Study of
74
- Jul 18, 2020
NCT04407442: Phase 2: Dara, Azacitidine & Dex for RRMM Myeloma Previously Treated With Daratumumab
NCT04407442: Phase 2: Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab This phase II trial studies how well daratumumab, azacitidine, and dexamethasone work in treating patients with multiple myeloma that has come back (recur
86
- Jul 18, 2020
NCT04430894: Phase 2: KRDI in Transplant-Eligible MM
NCT04430894: Phase 2: KRDI in Transplant-Eligible MM KRDI in Transplant-Eligible MM This research study is testing the efficacy of an experimental drug combination for people with newly diagnosed multiple myeloma that are eligible for a stem cell transplant. The names of the study drugs involved in this study are: Carfilzomib Isatuximab Lenalidomide Dexamethasone Sponsor: Massachusetts General Hospital Collaborators: Amgen Sanofi ClinicalTrials.gov Identifier: NCT04430894 Off
91
- Jul 17, 2020
NYC-Miami Myeloma MRD 2020 Virtual Meeting, 8th of October 2020
VJHemOnc was official media partner of the NYC-Miami Myeloma MRD 2020 Virtual Meeting which took place on the 8th of October 2020 and was organized by MMRF & Memorial Sloan Kettering Cancer Center. The meeting brought together leading experts in multiple myeloma who discussed the use of measurable residual disease (MRD) in clinical and trial settings, furthering our understanding of recent advances in the disease, and encouraging interactive discussion. Learn more : https://w
70
- Jul 17, 2020
NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 Relapsed Refractory Myeloma
NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple myeloma. Sponsor CRISPR Therapeutics AG Multiple locations International study ClinicalTrials.gov Identifier: NCT04244656 A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Effi
143
- Jul 16, 2020
Myeloma UK Publication, intended for UK Audience: Infopack for newly diagnosed patients
Myeloma UK Publication, intended for UK Audience Infopack for newly diagnosed multiple myeloma NDMM https://www.myeloma.org.uk/ https://www.myeloma.org.uk/publications/ Infopack for newly diagnosed patients Click here to view online publication
96
- Jul 16, 2020
NCT04302324: Phase 2: Daratumumab, Clarithromycin, Pomalidomide And Dex RRMM - D-ClaPd
D-ClaPd NCT04302324: Phase 2: A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab NCT04302324: Phase 2: A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab This is a single-center single-arm phase 2 study in which patients will receive daratumumab in combination with clarithrom
46
- Jul 16, 2020
NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dex RRMM
NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma Open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics and initial efficacy of AO-176 as monotherapy and in combination with dexamethasone and bortezomib in adu
115
- Jul 15, 2020
NCT04309981: Phase 1/2: Humanized CART Directed Against BCMA (ARI0002h) in RRMM Multiple Myeloma
NCT04309981: Phase 1/2: Humanized CART Directed Against BCMA (ARI0002h) in RRMM to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody. Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody. To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with p
168
- Jul 11, 2020
NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)
The ADVANCE trial Dara-KRd KRd VRd NCT04268498: A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (ADVANCE) This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the standard of care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).
548
- Jul 11, 2020
NCI - National Cancer Institute : How Monoclonal Antibodies Treat Cancer?
How Monoclonal Antibodies Treat Cancer? Daratumumab is a monoclonal antibody against CD38, molecules present on myeloma cancer cells. Monoclonal Antibodies and Their Side Effects (www.cancer.org) One way the body's immune system attacks foreign substances is by making large numbers of antibodies. An antibody is a protein that sticks to a specific protein called an antigen. Antibodies circulate throughout the body until they find and attach to the antigen. Once attached, they
190
- Jul 11, 2020
NCT04394650: Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM
CC-98633
CART NCT04394650: Phase 1 - A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in subjects with relapsed and/or refractory multiple myeloma. The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The dose-escalation part (P
193
- Jul 11, 2020
Allogenic CAR T Explained by Precision BioSciences
Allogenic CAR T Explained by Precision BioSciences
83